Prudential Financial’s Cymabay Therapeutics CBAY Stock Holding History

Prudential Financial’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-233,921	Closed	-$5.53M	–	2785
2023 Q4	$5.53M	Sell	233,921 -8,056	-3%	-$143K	0.01%	888
2023 Q3	$3.76M	Buy	241,977 +867	+0.4%	+$11.5K	0.01%	1020
2023 Q2	$2.64M	Buy	+241,110	New	+$2.24M	﹤0.01%	1237

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prudential Financial's CBAY Position: Q1 2024 in Review

Prudential Financial sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 233,921 shares — an estimated $5.53M sold.

Prudential Financial first reported a position in CBAY in Q2 2023 and held it in 3 quarters. The position peaked at $5.53M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Prudential Financial reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Prudential Financial sold 233,921 Cymabay Therapeutics shares in Q1 2024, an estimated $5.53M.
Prudential Financial first reported a position in Cymabay Therapeutics in Q2 2023 and held it in 3 quarters.
Prudential Financial's Cymabay Therapeutics position peaked at $5.53M in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Prudential Financial's 13F filing for Q1 2024, filed 14 May 2024.